Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

Early Access Eligibility Criteria: * Written, signed, and dated informed patient/parent consent; and for patients who were minors, age-appropriate assent (performed according to local regulations) * Male or female patients at least 2 years of age * Genetically-confirmed diagnosis of PH1 * Accessible for treatment and follow-up and be able to comply with treatment monitoring requirements * Not eligible for an ongoing RNAi therapy trial and not participating simultaneously in any interventional clinical research study * Patients with PH1 that are not satisfactorily treated with current standard of care; i.e., 24-hour urinary oxalate (Uox) excretion ≥ 0.7 (millimoles) mmol for participants 18 years and older, or greater or lesser than (≥) 0.7 mmol per 1.73 metre square (m\^2) body surface area (BSA) for participants less than 18 years of age * Estimated GFR at screening ≥ 30 millilitres per minute (mL/min) normalized to 1.73 m\^2 BSA * No renal or hepatic transplantation; prior or planned within the treatment period * No documented evidence of clinical manifestations of systemic oxalosis (including pre existing retinal, heart, or skin calcifications, or history of severe bone pain, pathological fractures, or bone deformations) * Patient not currently on dialysis * Plasma oxalate ≤ 30 micromoles per litre (μmol/L) * Female patients not breastfeeding or pregnant * The potential benefit for the individual patient justifies the potential risks of treatment as per prescribing physic…